Cargando…
Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial
Today there is plausible evidence both on experimental and epidemiological basis, that hyperuricemia represents a risk factor for the development and progression of chronic kidney disease (CKD). Nevertheless, the role of serum uric acid lowering treatment in CKD is still a matter of serious controve...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512148/ https://www.ncbi.nlm.nih.gov/pubmed/28748122 http://dx.doi.org/10.1016/j.jare.2017.05.001 |
_version_ | 1783250450332516352 |
---|---|
author | Eleftheriadis, Theodoros Golphinopoulos, Spyridon Pissas, Georgios Stefanidis, Ioannis |
author_facet | Eleftheriadis, Theodoros Golphinopoulos, Spyridon Pissas, Georgios Stefanidis, Ioannis |
author_sort | Eleftheriadis, Theodoros |
collection | PubMed |
description | Today there is plausible evidence both on experimental and epidemiological basis, that hyperuricemia represents a risk factor for the development and progression of chronic kidney disease (CKD). Nevertheless, the role of serum uric acid lowering treatment in CKD is still a matter of serious controversy. Review of randomised controlled trials, suggests that there may be an improvement of renal function with allopurinol treatment in CKD stage 3–5. However, these studies have included a relatively limited number of participants and provide insufficient information on adverse events and on the incidence of the end stage renal disease. Therefore, before adequately powered randomised, placebo-controlled trials are completed we cannot recommend treating asymptomatic hyperuricemia in patients with CKD. |
format | Online Article Text |
id | pubmed-5512148 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-55121482017-07-26 Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial Eleftheriadis, Theodoros Golphinopoulos, Spyridon Pissas, Georgios Stefanidis, Ioannis J Adv Res Review Today there is plausible evidence both on experimental and epidemiological basis, that hyperuricemia represents a risk factor for the development and progression of chronic kidney disease (CKD). Nevertheless, the role of serum uric acid lowering treatment in CKD is still a matter of serious controversy. Review of randomised controlled trials, suggests that there may be an improvement of renal function with allopurinol treatment in CKD stage 3–5. However, these studies have included a relatively limited number of participants and provide insufficient information on adverse events and on the incidence of the end stage renal disease. Therefore, before adequately powered randomised, placebo-controlled trials are completed we cannot recommend treating asymptomatic hyperuricemia in patients with CKD. Elsevier 2017-09 2017-05-05 /pmc/articles/PMC5512148/ /pubmed/28748122 http://dx.doi.org/10.1016/j.jare.2017.05.001 Text en © 2017 Production and hosting by Elsevier B.V. on behalf of Cairo University. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Eleftheriadis, Theodoros Golphinopoulos, Spyridon Pissas, Georgios Stefanidis, Ioannis Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial |
title | Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial |
title_full | Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial |
title_fullStr | Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial |
title_full_unstemmed | Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial |
title_short | Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial |
title_sort | asymptomatic hyperuricemia and chronic kidney disease: narrative review of a treatment controversial |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512148/ https://www.ncbi.nlm.nih.gov/pubmed/28748122 http://dx.doi.org/10.1016/j.jare.2017.05.001 |
work_keys_str_mv | AT eleftheriadistheodoros asymptomatichyperuricemiaandchronickidneydiseasenarrativereviewofatreatmentcontroversial AT golphinopoulosspyridon asymptomatichyperuricemiaandchronickidneydiseasenarrativereviewofatreatmentcontroversial AT pissasgeorgios asymptomatichyperuricemiaandchronickidneydiseasenarrativereviewofatreatmentcontroversial AT stefanidisioannis asymptomatichyperuricemiaandchronickidneydiseasenarrativereviewofatreatmentcontroversial |